Medication info
Polminlina Controlled-Release Tablets 5/1000 mg (Linagliptin, Metformin Hydrochloride)

Polminlina Controlled-Release Tablets 5/1000 mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Micronized›5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Green Cross Corp.
Appearance
White oval controlled-release film-coated tablets
Packaging
30 tablets / bottle
Approval status
Active

MFDS item code 202400694 · Approved 2024.03.29 · Insurance code 643606670

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. Take this medicine once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take 1 tablet of this medicine 5/1000 mg extended-release once daily. Patients taking this medicine 2.5/1000 mg extended-release should take 2 tablets at the same time once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg; the dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be needed to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and dosage adjustments made as appropriate, if needed. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, use the current doses of linagliptin and extended-release metformin hydrochloride. Special populations Renal impairment Because dosage adjustment may be needed according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) ≥45mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≥45mL/min/1.73m2 and <60mL/min/1.73m2, this medicine may be used with dose adjustment of metformin hydrochloride as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) falls below 45mL/min or estimated glomerular filtration rate (eGFR) falls below 45mL/min/1.73m2, this medicine must be discontinued immediately.

Ingredients

Manufacturer
Green Cross Corp.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps control blood sugar in patients with type 2 diabetes by using a combination of linagliptin and metformin. It is suitable for patients who also engage in dietary control and exercise therapy, aiding in effective management of blood sugar levels. This helps reduce the risk of diabetes complications and improve overall health.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. Take this medicine once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take 1 tablet of this medicine 5/1000 mg extended-release once daily. Patients taking this medicine 2.5/1000 mg extended-release should take 2 tablets at the same time once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg; the dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be needed to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and dosage adjustments made as appropriate, if needed. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, use the current doses of linagliptin and extended-release metformin hydrochloride. Special populations Renal impairment Because dosage adjustment may be needed according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) ≥45mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≥45mL/min/1.73m2 and <60mL/min/1.73m2, this medicine may be used with dose adjustment of metformin hydrochloride as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) falls below 45mL/min or estimated glomerular filtration rate (eGFR) falls below 45mL/min/1.73m2, this medicine must be discontinued immediately.

Precautions

This medication contains two components, metformin and linagliptin, and is primarily used for the treatment of type 2 diabetes. This medication can rarely cause a serious condition called lactic acidosis, so patients with poor kidney function or acute illness should not use it. Patients who are allergic to any ingredients or components of this medication, as well as patients with type 1 diabetes or severe liver dysfunction, should also avoid taking it. This medication may cause hypoglycemia; therefore, caution is especially needed when used in conjunction with other hypoglycemic agents like insulin or sulfonylureas. Elderly patients with weakened kidney function or situations where acute kidney injury is a concern may require dose adjustment and kidney function monitoring. Adverse effects such as acute pancreatitis or bullous skin diseases may occur, so if severe abdominal pain or skin abnormalities arise during treatment, notify a doctor immediately. This medication may lower vitamin B12 levels, so it is important to regularly check for vitamin B12 deficiency if taken for an extended period. When taking this medication, do not crush or chew the tablets; swallow them whole, and it is normal for the tablet coating to appear in the stool. This medication may interact with certain other drugs, so patients taking other medications should consult a doctor or pharmacist. Pregnant or breastfeeding women are advised not to use this medication, and those planning to become pregnant should consult a doctor. Safety for pediatric patients has not been established, and elderly patients should adjust the dose according to kidney function and routinely monitor kidney function. In cases of overdose, serious side effects like lactic acidosis may occur, so it is important to adhere strictly to the recommended dosage and seek medical attention immediately if any abnormal symptoms appear. Store this medication out of reach of children, avoiding moisture and not transferring it to other containers.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • angioedema
  • urticaria
  • lactic acidosis
  • abnormal vitamin B12 absorption test
  • hypoglycemia
  • taste disorder
  • cough
  • loss of appetite
Show 144 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • pseudo-pemphigus
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity reactions
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuritis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer's type dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot disease
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • cholelithiasis
  • dizziness
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • palpitations
  • dry eye
  • glaucoma
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • hearing loss
  • erectile dysfunction
  • thyroid goiter
  • kidney transplant failure
  • anemia
  • nausea
  • gastroesophageal reflux disease
  • gastritis
  • viral upper respiratory infection
  • upper respiratory infection
  • gastroenteritis
  • herpes zoster
  • periodontitis
  • influenza
  • mediastinitis
  • pharyngitis
  • rhinitis
  • dizziness
  • sensory loss
  • chest discomfort
  • asthenia
  • pain
  • nosebleed
  • oropharyngeal pain
  • speech disorder
  • epistaxis
  • rhinorrhea
  • pulmonary mass
  • arthralgia
  • osteoporosis
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome
  • elevated triglycerides
  • increased urine albumin/creatinine ratio
  • positive urine leukocytes
  • decreased hemoglobin
  • elevated potassium levels
  • increased serum creatinine
  • increased serum creatine kinase activity
  • increased ALT
  • male-pattern hair loss
  • hyperhidrosis
  • hair loss
  • dermatitis
  • anxiety
  • confusion
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from exposure to air or moisture. It is important to maintain a storage temperature between 1°C and 30°C.

Appearance and packaging

Appearance

White oval controlled-release film-coated tablets

Package unit

30 tablets / bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.